We would like to thank Dr. Scharf for the supportive comments on our work.1 We agree that analyses on other heart rhythm markers of atrial cardiopathy apart from atrial fibrillation would be of interest. However, due to the paucity of evidence on the implication of these markers on patient outcomes, no meaningful conclusions can be derived. The effect of anticoagulation on stroke recurrence in patients with evidence of atrial cardiopathy is currently being investigated in the ongoing Atrial Cardiopathy and Antithrombotic Drugs in Prevention after Cryptogenic Stroke trial (NCT03192215). Indeed, delineating recurrent stroke mechanisms in outcome events is important, but the reduction of the overall stroke risk burden should still be the primary end point for a large randomized controlled clinical trial. As stated in the conclusions of our abstract and highlighted by Dr. Scharf, the stroke community should wait for robust evidence from large-scale trials, evaluating the potential benefit of anticoagulation initiation prompted by prolonged cardiac monitoring within stroke prevention practices.